Circulating free DNA in plasma or serum as biomarker of carcinogenesis: practical aspects and biological significance.
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
MetadataShow full item record
AbstractThe presence of small amounts of tumor DNA in cell free DNA (CFDNA) circulating in the plasma or serum of cancer patients was first demonstrated 30 years ago. Since then, overall plasma DNA concentration in cancer patients and genetic or epigenetic alterations specific to tumor DNA have been investigated in patients diagnosed with different types of cancer. The proportion of patients with altered CFDNA varies with the pathology and the nature of the marker. However, several studies have reported the presence of altered CFDNA in over 50% of cancer patients, suggesting that this marker may be common and amenable for a variety of clinical and epidemiological studies. Because the mechanisms and timing of CFDNA release in the blood stream are poorly understood, only few studies have addressed the use of CFDNA for early cancer detection or as a biomarker for mutagenesis and tumourigenesis in molecular epidemiology. In this review, we discuss the technical issues involved in obtaining, using and analyzing CFDNA in cancer or healthy subjects. We also summarize the literature available on the mechanisms of CDNA release as well as on cross-sectional or prospective studies aimed at assessing the clinical and biological significance of CFDNA. These studies show that, in some circumstances, CFDNA alterations are detectable ahead of cancer diagnosis, raising the possibility of exploiting them as biomarkers for monitoring cancer occurrence. Testing these hypotheses will require well-designed studies, assessing multiple markers with quantitative and sensitive methods, with adequate follow-up of subjects, and we provide recommendations for the development of such studies.
CitationMutat. Res. 635 (2-3):105-117
Sponsorshe authors of this paper are partners of European Cancer Risk, Nutrition and Individual Susceptibility (ECNIS), a network of excellence operating within the European Union 6th Framework Program, Priority 5: “Food Quality and Safety” (Contract No. 513943). The work on plasma DNA at IARC was partially supported by the Compagnia di San Paolo (Torino, Italy), the Lega Italiana per la lotta contro I tumori and the European Community (GENAIR programme, QL4-1999-000927).
- Cell-free DNA in the blood as a solid tumor biomarker--a critical appraisal of the literature.
- Authors: Jung K, Fleischhacker M, Rabien A
- Issue date: 2010 Nov 11
- Circulating plasma DNA as diagnostic biomarker in non-small cell lung cancer.
- Authors: Paci M, Maramotti S, Bellesia E, Formisano D, Albertazzi L, Ricchetti T, Ferrari G, Annessi V, Lasagni D, Carbonelli C, De Franco S, Brini M, Sgarbi G, Lodi R
- Issue date: 2009 Apr
- Circulating tumour-derived DNA and RNA markers in blood: a tool for early detection, diagnostics, and follow-up?
- Authors: Bremnes RM, Sirera R, Camps C
- Issue date: 2005 Jul
- Circulating free tumor DNA and colorectal cancer.
- Authors: Lecomte T, Ceze N, Dorval E, Laurent-Puig P
- Issue date: 2010 Dec
- Optimizing the yield and utility of circulating cell-free DNA from plasma and serum.
- Authors: Xue X, Teare MD, Holen I, Zhu YM, Woll PJ
- Issue date: 2009 Jun 27